Lynette Smith, PhD

Articles by Lynette Smith, PhD

This trial combines pembrolizumab and trabedersen to enhance treatment for advanced NSCLC, targeting TGF-β2 for improved patient outcomes.

Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed PD-L1–Positive Metastatic NSCLC

ByOmar K. Abughanimeh, MBBS,Anthony E. Maida III, PhD, MA, MBA,Sanjive Qazi, PhD,Kate-Lynn Muir, DO,Bhavina Sharma MD,Lynette Smith, PhD,Apar Kishor Ganti, MD

October 30th 2025

A Phase 2 Study of Docetaxel and Capecitabine in Advanced Squamous Cell Carcinoma of the Head and Neck

ByOmar K. Abughanimeh, MBBS,Nicole A. Shonka, MD,Jane Meza, PhD,Lynette Smith, PhD,Irfan A. Vaziri, MD,Mehmet Sitki Copur, MD,Robin High, MBA,Kimberly Shields, BSN, RN,Holly DeSpiegelaere, BSN, RN,Anne Kessinger, MD,Apar Kishor Ganti, MD, MS

August 13th 2025

This study explores the efficacy and safety of combining docetaxel and capecitabine for treating recurrent or metastatic head and neck cancer.

Latest Updated Articles

A Phase 2 Study of Docetaxel and Capecitabine in Advanced Squamous Cell Carcinoma of the Head and Neck
August 13th 2025
Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed PD-L1–Positive Metastatic NSCLC
October 30th 2025

Trending on CancerNetwork

FDA Approves SC Amivantamab for Recurrent/Metastatic HNSCC

Setting Up an HDR Brachytherapy Program Amid a National Decline

Zamto-Cel Improves EFS vs R-GemOx in Transplant-Ineligible R/R LBCL

16-Fraction PMRT With IMN Irradiation Noninferior in High-Risk Breast Cancer

CD38-Targeted Immuno-PET Helps Detect Active Multiple Myeloma